New fatal warning for SGLT2 inhibitor drugs
Health authorities have issued a warning about potential fatal risks associated with the use of dapagliflozin, empagliflozin, and canagliflozin. The alert applies to all patients taking these medications, without specifying individual cases.
Free brief. We compared the headlines reported by the outlets below; the full articles were not verified.
- New 'fatal' warning for anyone on dapagliflozin, empagliflozin or canagliflozin
The list of sources is shown to subscribers.See plans
Sources checked
The list of sources is shown to subscribers.See plans
Links point to the original publishers. VERITY is not affiliated with them.
Other languages
Recently published
VERITY is an information service, not a news organization. Summaries are written by our AI and reviewed before publication.